PANGU INNOVATION Corp.
Update：2026/08/14
Industries
Main Industry
Biotechnology
Main Product/Service
Oocyte Reprogramming Technology
Founded Year
2026
Unified Business No.
60365886
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,250,000 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PANGU INNOVATION was established in Taiwan by Nuwa Reprogramming, a startup founded on technology originating from the team of John B. Gurdon, a Nobel Prize laureate in Physiology or Medicine. The company focuses on the research and development of regenerative medicine and cell reprogramming technologies. With “oocyte molecular reprogramming technology” at its core, the company promotes cellular rejuvenation through epigenetic regulatory mechanisms and is committed to developing safe anti-aging and regenerative medicine solutions with clinical application potential. Compared to traditional induced pluripotent stem cell (iPSC) technology, PANGU INNOVATION employs a non-gene-insertion cell reprogramming strategy, which reduces the safety risks associated with genetic modification and enhances the controllability of the cell rejuvenation process. The company also leverages Taiwan’s industrial strengths in clinical medicine, biotech manufacturing, and artificial intelligence applications to advance the development and application of cell reprogramming technology in the fields of regenerative medicine and precision medicine.
